214 related articles for article (PubMed ID: 19734799)
1. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
Varghese V; Shahriar R; Rhee SY; Liu T; Simen BB; Egholm M; Hanczaruk B; Blake LA; Gharizadeh B; Babrzadeh F; Bachmann MH; Fessel WJ; Shafer RW
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):309-15. PubMed ID: 19734799
[TBL] [Abstract][Full Text] [Related]
2. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Reuman EC; Rhee SY; Holmes SP; Shafer RW
J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
[TBL] [Abstract][Full Text] [Related]
3. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
4. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
[TBL] [Abstract][Full Text] [Related]
5. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
6. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
7. [Resistance profile of rilpivirine].
Imaz A; García F; di Yacovo S; Llibre JM
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
[TBL] [Abstract][Full Text] [Related]
8. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
[TBL] [Abstract][Full Text] [Related]
11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
12. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
[TBL] [Abstract][Full Text] [Related]
13. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
[TBL] [Abstract][Full Text] [Related]
14. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
Halvas EK; Wiegand A; Boltz VF; Kearney M; Nissley D; Wantman M; Hammer SM; Palmer S; Vaida F; Coffin JM; Mellors JW
J Infect Dis; 2010 Mar; 201(5):672-80. PubMed ID: 20102272
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
[TBL] [Abstract][Full Text] [Related]
16. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
17. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C
AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
[TBL] [Abstract][Full Text] [Related]
19. Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.
Agneskog E; Nowak P; Maijgren Steffensson C; Casadellà M; Noguera-Julian M; Paredes R; Källander CF; Sönnerborg A
PLoS One; 2014; 9(7):e101508. PubMed ID: 25000302
[TBL] [Abstract][Full Text] [Related]
20. Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Delviks-Frankenberry KA; Lengruber RB; Santos AF; Silveira JM; Soares MA; Kearney MF; Maldarelli F; Pathak VK
Virology; 2013 Jan; 435(2):433-41. PubMed ID: 23068886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
